GLP-1 vs Metformin for Weight Loss: What's the Difference?

# GLP-1 vs Metformin for Weight Loss: What's the Difference?

Two medications dominate the conversation around medically supervised weight loss: GLP-1 receptor agonists (semaglutide, tirzepatide) and metformin. Both are prescribed by physicians; both have metabolic benefits beyond weight loss; both are available at significantly lower cost through compounding pharmacies.

But they work very differently, and the results aren't comparable.

What Metformin Does

Metformin is a biguanide that's been prescribed for type 2 diabetes since the 1990s. It's one of the most-prescribed medications in the world. Its primary mechanism: reducing hepatic glucose production (the liver dumps less glucose into the bloodstream) and modestly improving insulin sensitivity.

For weight loss, metformin has a real but modest effect. Clinical data shows average weight reduction of 1–3 kg (2–7 lbs) over 6–12 months — meaningful in the context of diabetes management, underwhelming as a primary weight loss strategy.

Some research suggests metformin may also reduce appetite slightly and affect the gut microbiome in ways that influence weight, but these effects are not well characterized and the clinical impact is small.

Why people take it: Low cost (often under $10/month generic), decades of safety data, metabolic benefits including cardiovascular protection, possible longevity effects (it's being studied in the TAME trial for aging).

What GLP-1 Agonists Do

GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) work through a fundamentally different and more powerful mechanism.

GLP-1 (glucagon-like peptide-1) is a gut hormone naturally released after eating. It: - Signals the brain to reduce appetite and food intake - Slows gastric emptying (food leaves your stomach more slowly, keeping you full longer) - Reduces food cravings and "food noise" — the constant preoccupation with eating - Improves insulin sensitivity and glucose metabolism - In the case of tirzepatide, also acts on GIP receptors, amplifying these effects

The result is dramatically more significant weight loss. In clinical trials: - Semaglutide: Average 15–17% body weight reduction over 68 weeks - Tirzepatide: Average 20–22% body weight reduction over 72 weeks

For a 220-pound man, that's 33–48 lbs of weight loss on average — with many patients losing significantly more.

The Combination Approach

Some physicians prescribe metformin alongside GLP-1 therapy for specific patients, particularly those with insulin resistance or prediabetes. The rationale: metformin's insulin-sensitizing effects may complement GLP-1's appetite suppression, potentially improving outcomes while reducing GLP-1 dose requirements.

The evidence for this combination is still emerging. It's most defensible for patients who are already on metformin for metabolic reasons and adding GLP-1 therapy, rather than adding metformin specifically to enhance GLP-1 effects.

Side Effect Profiles: Very Different

Metformin: Primarily GI side effects — nausea, diarrhea, cramping — most pronounced at initiation and with higher doses. Extended-release formulations significantly reduce these. Rarely, metformin can cause B12 deficiency with long-term use. Serious adverse effects are uncommon.

GLP-1 agonists: Also primarily GI — nausea, constipation, reduced appetite (which is therapeutic but can be uncomfortable), occasional vomiting. These are dose-dependent and typically improve after the first 4–8 weeks. More significant but rare: pancreatitis risk (unclear causality in clinical data), gallbladder issues with rapid weight loss.

Cost Comparison

Metformin generic: $4–15/month. Extremely accessible.

Brand-name semaglutide (Wegovy/Ozempic): $1,000–1,300/month without insurance. Often inaccessible without coverage.

Compounded semaglutide (Marrow): Starting around $149/month — same molecule, dramatically lower cost, clinically equivalent efficacy.

Compounded tirzepatide (Marrow): Starting around $199/month.

This is why the compounded GLP-1 market has exploded: the results are incomparable to metformin, and the cost is now in the same order of magnitude for patients without insurance coverage.

Who Gets Which?

Metformin alone makes sense for: - Type 2 diabetes management (weight loss is a secondary benefit) - Prediabetes with only modest weight loss goals - Patients who can't tolerate GLP-1 side effects - Cost-constrained situations where even compounded GLP-1 is out of reach - Patients seeking longevity/metabolic benefits with minimal intervention

GLP-1 therapy makes sense for: - BMI ≥30, or BMI ≥27 with metabolic comorbidities (diabetes, hypertension, sleep apnea) - Patients who've tried lifestyle modification without sufficient results - Anyone with significant weight loss goals (>10–15% of body weight) - Patients motivated by the dramatic outcomes in clinical trials

Both together: Most commonly seen in patients with T2D or significant insulin resistance who are adding GLP-1 to existing metformin treatment.

The Bottom Line

Metformin is a good drug for metabolic health. It's not a meaningful weight loss tool for most people.

GLP-1 medications represent a genuine paradigm shift in weight management — the most effective pharmaceutical approach ever developed for obesity. If your goal is substantial, sustained weight loss with a medically supervised protocol, GLP-1 therapy is the current standard of care.

Marrow prescribes both metformin (for appropriate candidates) and compounded GLP-1 medications, and our physicians will help you understand which protocol makes sense for your specific metabolic picture and goals.